Literature DB >> 24328909

Prevalence of hypercoagulable disorders in inflammatory bowel disease.

Darina Kohoutova1, Miroslav Pecka, Michal Cihak, Jiri Cyrany, Jaroslav Maly, Jan Bures.   

Abstract

OBJECTIVE. Inflammatory bowel disease (IBD) can be associated with hypercoagulable disorders. Aim of this single-center, prospective study was an in-depth evaluation of acquired hypercoagulable states in IBD patients. METHODS. A total of 110 patients with Crohn's disease (CD) (aged 19-69; mean 40.5, median 38.5 years), 43 with ulcerative colitis (UC) (aged 17-72; mean 42, median 36 years), and 30 controls were enrolled. Full blood count, serum C-reactive protein (CRP), proteins C and S, activated protein C (APC) resistance, thrombin-antithrombin complex (TAT), F1+F2 fragments, tissue factor pathway inhibitor (TFPI) total and truncated, TFPI-factor Xa, tissue plasminogen activator (tPA) and PAI-I antigen were investigated in peripheral blood samples. RESULTS. Only 18 of 153 (11.8%) IBD patients had hemocoagulation parameters within normal range. Significant difference between IBD patients and controls was found in thrombocyte volume (p < 0.001), protein C (p = 0.025), protein S (p = 0.003), APC resistance (p < 0.001), F1+F2 fragments (p < 0.001), and tPA (p = 0.002). In CD patients who were divided into two subgroups according to serum CRP values (non-active disease: <5 mg/L; active disease ≥5 mg/L), thrombocyte count was significantly lower (p = 0.001), thrombocyte volume was significantly higher (p = 0.002), F1+F2 fragments were significantly lower (p = 0.007) and tPA was significantly higher (p = 0.038) in the subgroup with CRP <5 mg/L. In UC patients, no significant difference depending on CRP was found. CONCLUSIONS. Acquired hypercoagulable abnormalities in IBD patients are frequent. Patients with active CD, but not UC, displayed significantly different hemocoagulable parameters, when compared to non-active CD/UC subjects. In patients with active CD (with increased serum CRP concentration) and patients with active extensive UC found at endoscopy (despite low CRP values), prophylactic anticoagulation therapy should be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24328909     DOI: 10.3109/00365521.2013.870597

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease.

Authors:  Adler Shing Chak Ma; Iain Ewing; Charles Daniel Murray; Mark Ian Hamilton
Journal:  BMJ Case Rep       Date:  2015-05-04

2.  PAI-1 augments mucosal damage in colitis.

Authors:  Gerard E Kaiko; Feidi Chen; Chin-Wen Lai; I-Ling Chiang; Jacqueline Perrigoue; Aleksandar Stojmirović; Katherine Li; Brian D Muegge; Umang Jain; Kelli L VanDussen; Bridie J Goggins; Simon Keely; Jessica Weaver; Paul S Foster; Daniel A Lawrence; Ta-Chiang Liu; Thaddeus S Stappenbeck
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

Review 3.  Thromboembolic complications in inflammatory bowel disease.

Authors:  Darina Kohoutova; Paula Moravkova; Peter Kruzliak; Jan Bures
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

4.  Identification of Candidate Genes Related to Inflammatory Bowel Disease Using Minimum Redundancy Maximum Relevance, Incremental Feature Selection, and the Shortest-Path Approach.

Authors:  Fei Yuan; Yu-Hang Zhang; Xiang-Yin Kong; Yu-Dong Cai
Journal:  Biomed Res Int       Date:  2017-02-14       Impact factor: 3.411

5.  A Patient with Ulcerative Colitis Complicated by Systemic Vein Thrombosis.

Authors:  Antonio Meštrović; Ivan Žaja; Žarko Ardalić; Pavle Vrebalov-Cindro; Ivan Šustić; Marko Puljiz; Andre Bratanić; Damir Bonacin
Journal:  Case Rep Gastroenterol       Date:  2018-06-25

6.  Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol.

Authors:  Péter Hegyi; Judit Bajor; Zsolt Szakács; Beáta Csiszár; Péter Kenyeres; Patrícia Sarlós; Bálint Erőss; Alizadeh Hussain; Ágnes Nagy; Balázs Kőszegi; Ibolya Veczák; Nelli Farkas; Emőke Bódis; Katalin Márta; Andrea Szentesi; Margit Tőkés-Füzesi; Tímea Berki; Áron Vincze; Kálmán Tóth
Journal:  BMJ Open       Date:  2019-03-23       Impact factor: 2.692

7.  Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.

Authors:  Jean-Paul Motta; Simone Palese; Carmine Giorgio; Kevin Chapman; Alexandre Denadai-Souza; Perrine Rousset; David Sagnat; Laura Guiraud; Anissa Edir; Carine Seguy; Laurent Alric; Delphine Bonnet; Barbara Bournet; Louis Buscail; Cyrielle Gilletta; Andre G Buret; John L Wallace; Morley D Hollenberg; Eric Oswald; Elisabetta Barocelli; Sylvie Le Grand; Bruno Le Grand; Celine Deraison; Nathalie Vergnolle
Journal:  J Crohns Colitis       Date:  2021-05-04       Impact factor: 9.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.